Outlook Therapeutics (OTLK) Common Equity: 2015-2019
Historic Common Equity for Outlook Therapeutics (OTLK) over the last 5 years, with Sep 2019 value amounting to -$16.1 million.
- Outlook Therapeutics' Common Equity rose 267.27% to $11.0 million in Q2 2020 from the same period last year, while for Jun 2020 it was $11.0 million, marking a year-over-year increase of 267.27%. This contributed to the annual value of -$16.1 million for FY2019, which is 36.86% up from last year.
- Latest data reveals that Outlook Therapeutics reported Common Equity of -$16.1 million as of FY2019, which was up 36.86% from -$25.5 million recorded in FY2018.
- Outlook Therapeutics' Common Equity's 5-year high stood at -$5.2 million during FY2016, with a 5-year trough of -$54.9 million in FY2015.
- Its 3-year average for Common Equity is -$25.1 million, with a median of -$25.5 million in 2018.
- Its Common Equity has fluctuated over the past 5 years, first soared by 90.57% in 2016, then crashed by 550.52% in 2017.
- Outlook Therapeutics' Common Equity (Yearly) stood at -$54.9 million in 2015, then soared by 90.57% to -$5.2 million in 2016, then crashed by 550.52% to -$33.7 million in 2017, then increased by 24.09% to -$25.5 million in 2018, then soared by 36.86% to -$16.1 million in 2019.